iCardiac completes Series B funding
iCardiac Technologies has completed a Series B funding round to support further research into a personalized cardiac safety system, developed to assess cardiac risk associated with a range of on-market and in-development drugs.
Advantage Capital Partners, Stonehenge Growth Capital, Trillium Group and other investors, all provided an undisclosed amount of funding for the initiative.
The Rochester, N.Y.-based iCardiac did not disclose the financial terms of the second round of its venture capital.
Advantage Capital Partners, Stonehenge Growth Capital, Trillium Group and other investors, all provided an undisclosed amount of funding for the initiative.
The Rochester, N.Y.-based iCardiac did not disclose the financial terms of the second round of its venture capital.